Cataba­sis shares rock­et up on Duchenne pact with Sarep­ta; blue­bird whis­tles up a TCR deal with Medi­gene

The long line­up of new biotech deals we’re see­ing to­day con­tin­ues in the Pro­to­cols sec­tion, with more pacts from Sarep­ta and blue­bird.

Shares of Cataba­sis rock­et­ed up 56% this morn­ing on news of a new part­ner­ship. Fresh from win­ning the year’s most con­tro­ver­sial FDA ap­proval, Sarep­ta  $SRPT is part­ner­ing with Cataba­sis on a com­bo drug for Duchenne mus­cu­lar dy­s­tro­phy. Cataba­sis $CATB will pair its pre­clin­i­cal oral NF-kB in­hi­bi­tion pro­gram with one of Sarep­ta’s ex­on-skip­ping pro­grams.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.